Hoertel, Nicolas
Dosquet, Marie
Sánchez-Rico, Marina http://orcid.org/0000-0002-1121-8641
Godino-Cruz, Jesús
Blanco, Carlos
Aubin, Henri-Jean
Ducoutumany, Géraldine
Gorwood, Philip
Leleu, Henri
Airagnes, Guillaume
Lemogne, Cédric
Rezaei, Katayoun
Peyre, Hugo
Limosin, Frédéric
Article History
Accepted: 8 March 2024
First Online: 1 April 2024
Declarations
:
: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or the US government. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: FL has received speaker and consulting fees from the AstraZeneca, Janssen, Lundbeck, Otsuka Pharmaceuticals, Roche, and Servier, outside the submitted work. CL reports personal fees and non-financial support from the Lundbeck, personal fees from Janssen, non-financial support from the Otsuka Pharmaceuticals, outside the submitted work. PG received research grants from the Eli Lilly and Servier; honoraria for presentations in congresses from the AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, and Servier; participated in advisory board with the AstraZeneca, Janssen, Roche, and Servier; has a paid position at the University of Paris-Descartes and hospital Sainte-Anne, and no shares. HL has a paid position at the Public Health Expertise. GA has received speaker and consulting fees from the Lundbeck and Pfizer. HJA was member of advisory boards for the Pfizer, D&A Pharma, Ethypharm, Johnson& Johnson, and Lundbeck, and has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from the Bioprojet, D&A Pharma, Ethypharm, Lundbeck, and Pfizer. He is also member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE), which was supported in the last three years by the AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. Other authors (NH, MD, CB, GD, HP, MSR, JGC, KR) report no conflicts of interest relevant to the content of this article.